Literature DB >> 12813116

Effects of treating depression and low perceived social support on clinical events after myocardial infarction: the Enhancing Recovery in Coronary Heart Disease Patients (ENRICHD) Randomized Trial.

Lisa F Berkman1, James Blumenthal, Matthew Burg, Robert M Carney, Diane Catellier, Marie J Cowan, Susan M Czajkowski, Robert DeBusk, James Hosking, Allan Jaffe, Peter G Kaufmann, Pamela Mitchell, James Norman, Lynda H Powell, James M Raczynski, Neil Schneiderman.   

Abstract

CONTEXT: Depression and low perceived social support (LPSS) after myocardial infarction (MI) are associated with higher morbidity and mortality, but little is known about whether this excess risk can be reduced through treatment.
OBJECTIVE: To determine whether mortality and recurrent infarction are reduced by treatment of depression and LPSS with cognitive behavior therapy (CBT), supplemented with a selective serotonin reuptake inhibitor (SSRI) antidepressant when indicated, in patients enrolled within 28 days after MI. DESIGN, SETTING, AND PATIENTS: Randomized clinical trial conducted from October 1996 to April 2001 in 2481 MI patients (1084 women, 1397 men) enrolled from 8 clinical centers. Major or minor depression was diagnosed by modified Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria and severity by the 17-item Hamilton Rating Scale for Depression (HRSD); LPSS was determined by the Enhancing Recovery in Coronary Heart Disease Patients (ENRICHD) Social Support Instrument (ESSI). Random allocation was to usual medical care or CBT-based psychosocial intervention. INTERVENTION: Cognitive behavior therapy was initiated at a median of 17 days after the index MI for a median of 11 individual sessions throughout 6 months, plus group therapy when feasible, with SSRIs for patients scoring higher than 24 on the HRSD or having a less than 50% reduction in Beck Depression Inventory scores after 5 weeks. MAIN OUTCOME MEASURES: Composite primary end point of death or recurrent MI; secondary outcomes included change in HRSD (for depression) or ESSI scores (for LPSS) at 6 months.
RESULTS: Improvement in psychosocial outcomes at 6 months favored treatment: mean (SD) change in HRSD score, -10.1 (7.8) in the depression and psychosocial intervention group vs -8.4 (7.7) in the depression and usual care group (P<.001); mean (SD) change in ESSI score, 5.1 (5.9) in the LPSS and psychosocial intervention group vs 3.4 (6.0) in the LPSS and usual care group (P<.001). After an average follow-up of 29 months, there was no significant difference in event-free survival between usual care (75.9%) and psychosocial intervention (75.8%). There were also no differences in survival between the psychosocial intervention and usual care arms in any of the 3 psychosocial risk groups (depression, LPSS, and depression and LPSS patients).
CONCLUSIONS: The intervention did not increase event-free survival. The intervention improved depression and social isolation, although the relative improvement in the psychosocial intervention group compared with the usual care group was less than expected due to substantial improvement in usual care patients.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12813116     DOI: 10.1001/jama.289.23.3106

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  420 in total

1.  Depressive symptoms and all-cause mortality in unstable angina pectoris (from the Coronary Psychosocial Evaluation Studies [COPES]).

Authors:  William Whang; Daichi Shimbo; Ian M Kronish; W Lane Duvall; Howard Julien; Padmini Iyer; Matthew M Burg; Karina W Davidson
Journal:  Am J Cardiol       Date:  2010-10-15       Impact factor: 2.778

2.  Elevated depressive affect is associated with adverse cardiovascular outcomes among African Americans with chronic kidney disease.

Authors:  Michael J Fischer; Paul L Kimmel; Tom Greene; Jennifer J Gassman; Xuelei Wang; Deborah H Brooks; Jeanne Charleston; Donna Dowie; Denyse Thornley-Brown; Lisa A Cooper; Marino A Bruce; John W Kusek; Keith C Norris; James P Lash
Journal:  Kidney Int       Date:  2011-06-01       Impact factor: 10.612

Review 3.  Is there a high-risk subtype of depression in patients with coronary heart disease?

Authors:  Robert M Carney; Kenneth E Freedland
Journal:  Curr Psychiatry Rep       Date:  2012-02       Impact factor: 5.285

4.  A simultaneous test of the relationship between identified psychosocial risk factors and recurrent events in coronary artery disease patients.

Authors:  Keerat Grewal; Shannon Gravely-Witte; Donna E Stewart; Sherry L Grace
Journal:  Anxiety Stress Coping       Date:  2011-07

5.  Randomized controlled trial on the long-term efficacy of a multifaceted, interdisciplinary lifestyle intervention in reducing cardiovascular risk and improving lifestyle in patients at risk of cardiovascular disease.

Authors:  Lysanne Goyer; Robert Dufour; Caroline Janelle; Chantal Blais; Christine L'Abbé; Emilie Raymond; Jacques de Champlain; Pierre Larochelle
Journal:  J Behav Med       Date:  2012-03-09

6.  Social isolation associated with depression: a case report of hikikomori.

Authors:  Alan R Teo
Journal:  Int J Soc Psychiatry       Date:  2012-03-08

7.  Effect of obstructive sleep apnea on response to cognitive behavior therapy for depression after an acute myocardial infarction.

Authors:  Kenneth E Freedland; Robert M Carney; Junichiro Hayano; Brian C Steinmeyer; Rebecca L Reese; Annelieke M Roest
Journal:  J Psychosom Res       Date:  2012-01-28       Impact factor: 3.006

Review 8.  Psychosocial factors and coronary heart disease.

Authors:  Anders G Olsson
Journal:  Curr Atheroscler Rep       Date:  2004-01       Impact factor: 5.113

9.  Depression and CHD risk: how should we intervene?

Authors:  Susmita Parashar; Viola Vaccarino
Journal:  Curr Treat Options Cardiovasc Med       Date:  2007-08

10.  PURLs: SSRIs for depression/heart failure patients? Not so fast.

Authors:  Jason Ricco; Janice Benson; Shailendra Prasad
Journal:  J Fam Pract       Date:  2017-09       Impact factor: 0.493

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.